Maintenance dosing with tirzepatide: separating fact from assumption

The myth worth letting go: that everyone ends up on 15 mg

It is easy to see why this idea takes hold. The headline trial results (around 20–21% average body-weight reduction at the highest dose) come from the 15 mg arm of SURMOUNT-1, published in the New England Journal of Medicine. Those figures are cited widely, and 15 mg sounds like the goal. In practice, the licensed approach is more nuanced than that. The titration schedule exists precisely because tolerability varies enormously between people. Some people reach 15 mg without much difficulty; others find that 7.5 mg or 10 mg delivers good results with fewer side effects and stay there for months or longer. Neither outcome is a failure. The prescriber's job is to find the dose that works well for you, not to reach the top of the schedule for its own sake. That reassurance is worth sitting with before reading the rest of this page.

Tirzepatide is a dual GIP and GLP-1 receptor agonist, the only licensed weight-management medicine in the UK that activates both pathways. You can read more about how the medicine works on our Mounjaro overview page. The practical consequence of that dual action is that the effective dose point is genuinely individual; biological responses to GIP and GLP-1 signalling differ between people in ways that cannot be predicted in advance.

How the titration schedule actually works in practice

Treatment begins at 2.5 mg. That first pen's purpose is to let your system adjust, the gastrointestinal side effects that some people notice (nausea, loose stools, reduced appetite more sharply than expected) are typically most noticeable in the first few weeks, and starting low reduces their intensity. Our page on whether 2.5 mg can serve as a Mounjaro maintenance dose looks at the circumstances in which some people stay at this level for longer than the standard settling-in period.

After approximately four weeks, a prescriber reviews progress and tolerability before any dose increase. The same review logic applies at each subsequent step: 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. A step is only taken when the current dose is well tolerated and the clinical picture supports moving up. There is no automatic escalator. If side effects are bothersome at a given dose, staying at that level for longer (or not increasing further) is a legitimate clinical choice, not a setback. The NHS tirzepatide medicine page confirms the general titration structure and covers what to do if side effects arise at any point.

People sometimes ask whether 5 mg counts as a maintenance dose. The honest answer is: it can be, for some people. Our page on whether 5 mg Mounjaro is a maintenance dose looks at that question in more detail. The short version is that if someone is tolerating 5 mg well and their prescriber is satisfied with the clinical response, there is no requirement to increase further.

What determines where someone stabilises long-term

Several things shape where a person's dose settles. Tolerability is the first filter, if a dose increase brings persistent side effects, the prescriber may advise holding at the current level. The second is clinical response: if weight loss has reached a point where continuing at the current dose maintains that progress adequately, the case for pushing higher weakens. Third, individual biology matters; the dual-agonist mechanism means some people are notably more sensitive to GIP or GLP-1 signalling than others, and the dose needed to produce appetite suppression varies accordingly.

What this means for long-term planning is that how Mounjaro maintenance dosing works in practice is not a static endpoint you arrive at and then forget. Clinical reviews continue throughout treatment. At each review, a prescriber considers whether the current dose is still appropriate, whether to hold, increase, or, in some circumstances, reduce. If you are thinking about what that looks like in terms of ongoing costs and what a private prescription includes, our treatment and pricing overview explains what is covered. For a closer look at what the 15 mg data actually showed in the trial, the maintenance dose of tirzepatide page goes into the evidence in more depth.

Who is eligible and what the prescriber is assessing at each stage

The licensed eligibility criteria for tirzepatide cover adults with a BMI of 30 or above, or 27 and above where a weight-related condition is present, such as high blood pressure, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. NICE's technology appraisal (TA1026) sets slightly different criteria for NHS prescribing; private prescribing follows the licensed indications, which is why the two routes sometimes diverge on who qualifies.

At the maintenance stage specifically, the prescriber is not just asking whether the dose is tolerable. They are asking whether continuing at this dose, for this person, at this point in treatment, is still clinically appropriate. That is a different and more searching question than it sounds. If you are considering starting, our explainer on what a maintenance dose of tirzepatide means is a good starting point before a consultation. And if you are ready to speak to our prescribers, you can check your eligibility and start a free consultation with no obligation.